



DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors

Dottikon, Switzerland, July 4, 2008 – At the 3rd Annual General Meeting of DOTTIKON ES HOLDING AG for the business year 2007/08 carried out at the "Kultur- und Kongresszentrum TRAFÖ" in Baden, the shareholders approved all proposals of the Board of Directors. 123 present shareholders represented 1'065'696 voting rights and therefore 90.0% of the total of 1'184'154 registered shares with voting rights.

The annual report, financial statements 2007/08 and the consolidated financial report 2007/08 of the DOTTIKON ES HOLDING AG were approved by the Annual General Meeting. Further the proposal of the Board of Directors to allocate the entire retained earnings to other reserves and pay no dividend was accepted. Discharge for the business year 2007/08 was granted to the responsible Board of Directors and Management. All members of the Board, Heinz Boller, Dr. h.c. Peter Grogg and Dr. Robert Hofer, are reelected for an additional term of one year. Group auditors and statutory auditors for the present term is KPMG Ltd, Zurich.

DOTTIKON ES, with its production site in Dottikon (Aargau, Switzerland), is specialized in hazardous chemical reactions and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industry worldwide. The product range of DOTTIKON ES includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates as well as in-house-developed, high-value industrial chemicals.

DOTTIKON ES HOLDING AG is listed at the SWX Swiss Exchange.

Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

For further information please contact

Dr Markus Blocher
CEO

Dottikon ES Holding AG
Tel +41 56 616 82 01
Fax +41 56 616 89 45
investor-relations@dottikon.com